Jasbg, If the extent of my knowledge ended with the closing share price, I might see this situation the way that you do. The company has no debt, a substantial cash reserve, and a valuable product. This investment is now primarily dependent on European expansion. Preventing an event is less costly than post event treatment. Run the numbers. Most countries should eventually reimburse vazkepa at favorable prices. As far as US patent expiration??? You do understand, that is irrelevant beyond the legal front. Vascepa has almost no functional patent protection today. (In the US). A few people on this board questioned the wisdom of giving total control of the company to Alex Denner and his team of investment bankers. You attacked anyone that didn't support your boy. Perhaps not the best decision? I think the company will survive despite his interference. If you don't see the value in this company sell your position and watch some music videos.
Sleven,
Market Data 
Markets 
AI
